within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX08_Lenvatinib;

model Lenvatinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 1.9444444444444444e-06,
    adminDuration = 600,
    adminMass = 24 / 1000000,
    adminCount = 1,
    Vd = 0.1,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007116666666666666,
    Tlag = 10.020000000000001,
    Vdp = 0.053,
    k12 = 8.055555555555556e-06,
    k21 = 8.055555555555556e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lenvatinib</td></tr><tr><td>ATC code:</td><td>L01EX08</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>24</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>100</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lenvatinib is a multi-kinase inhibitor indicated for the treatment of certain types of cancer, including differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is an oral anticancer drug currently approved for use in several regions including the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic analysis in patients with advanced solid tumors, administered orally, typical adult population.</p><h4>References</h4><ol><li><p>Hu, Y, et al., &amp; Zeng, Y (2022). Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data. <i>Journal of clinical pharmacology</i> 62(12) 1507–1517. DOI:<a href=\"https://doi.org/10.1002/jcph.2103\">10.1002/jcph.2103</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35689595/\">https://pubmed.ncbi.nlm.nih.gov/35689595</a></p></li><li><p>Wei, Y, et al., &amp; Zhang, X (2023). Effects of diet and gender on the pharmacokinetics of oral lenvatinib: A clinical trial in healthy Chinese participants. <i>International journal of clinical pharmacology and therapeutics</i> 61(11) 475–481. DOI:<a href=\"https://doi.org/10.5414/CP204440\">10.5414/CP204440</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37644876/\">https://pubmed.ncbi.nlm.nih.gov/37644876</a></p></li><li><p>Gupta, A, et al., &amp; Hussein, Z (2016). Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. <i>British journal of clinical pharmacology</i> 81(6) 1124–1133. DOI:<a href=\"https://doi.org/10.1111/bcp.12907\">10.1111/bcp.12907</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26879594/\">https://pubmed.ncbi.nlm.nih.gov/26879594</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EX08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lenvatinib;
